Gene-based therapeutic strategies for cancer mainly packaging cell clone that produced a reasonable titer of include augmentation of immunotherapeutic and chemorecombinant virus and expressed high levels of IL-2 and tk therapeutic approaches. In this study we report the design transcripts. Although transduction efficiency was reduced and functional assay of a novel bicistronic Moloney-based in glioma cells as compared with murine NIH 3T3 cells, retroviral vector expressing human interleukin-2 (IL-2) and transgene expression was effectively achieved. Transherpesvirus thymidine kinase (tk) through a cap-dependent duced glioma cells were sensitive to ganciclovir and translation and an internal ribosome entry site (IRES)-regusecreted around 1000 U/ml IL-2 in the culture superlated translation, respectively. This construct has the natants. Simultaneous production of IL-2 and tk in vivo by potential for allowing combination of cytokine and suicide genetically treated tumor cells would hopefully potentiate gene therapy, especially in areas such as the brain, comthe effect of gangiclovir-induced metabolic suicide, posed of post-mitotic cells refractory to transduction by possibly by boosting the immune response associated type C retroviral vectors. Accordingly, human glioma cells with tumor debulking or by amplifying the bystander were used as targets for gene transfer after selecting a response.
Retroviral vectors, especially those derived from Moloney murine leukemia virus (MoMLV) are among the most utilized vectors in a number of gene therapy trials. Their efficiency relies upon the unique biological feature of retroviruses, ie the integration of the proviral genome into host chromosomes. This property guarantees that the transfer is constitutively acquired as a new genetic element by transduced somatic cells and progeny thereof. Genetic integration, at least for members of the Oncornavirinae of which Moloney is a prototype, requires an active state of cell proliferation. 1 Although this requirement may be viewed as a limitation for purposes such as genetic transfer into resting progenitor cells, it could turn into a clear advantage if selective expression of the transgene is to be achieved in actively proliferating neoplastic cells. Perhaps one of the main limitations of the practical use of retroviruses (RV) in a number of gene therapy approaches is the limited amount of genetic information that can be accommodated in their backbone and the almost exclusive ex vivo deployment. Approaches so far adopted for gene therapy of cancer include primarily gene-directed enzyme prodrug activation, cytokine production and stimulation of the immune system by the tumor cells. For each of the above strategies a single gene has generally been cloned in the vector, normally in association with a gene for positive selection. This basic design can saturate the vector expression capacity, which depends on the foreign gene complexity and promoter utilization. A simultaneous expression of two antitumor genes should ideally be achieved by the same vector in order to potentiate the anticancer effect. This, however, should not affect the vector titer or the expression of a reporter gene from a distinct transcription unit.
To prove the feasibility of this approach we have designed a bicistronic Moloney retrovirus vector (pLIL-2TKSN) to coexpress simultaneously IL-2 and tk together with a selectable marker gene (neomycin phosphotransferase (neo)). pLIL-2TKSN is based on the structure of pLXSN and pLIL-2SN. It contains the neo gene, driven by the simian virus 40 (SV40) early promoter, together with the human interleukin 2 (IL-2) and the herpes simplex virus type 1 thymidine kinase (tk) genes which are under control of the 5′ Moloney LTR. The latter genes are separated by an internal ribosome entry site (IRES) isolated from the encephalomyocarditis virus (ECMV). In the resulting vector, a single mRNA is transcribed under the control of the 5′ LTR promoter and it generates IL-2 through cap-dependent translation and tk following IRES-regulated translation. Since the neo gene is translated from a second transcript, pLIL-2TKSN results as a bicistronic triple gene vector (Figure 1) .
In order to obtain retroviral vectors for DNA delivery to human cells, we transfected the amphotropic packaging cell line PA317 with pLXSN, pLIL-2SN and pLIL-2TKSN retroviral vector containing plasmids. Pooled resistant populations were produced and viral titers were measured by counting G418-resistant colonies of infected NIH 3T3 target cells. A lower titer (Table 1 ) was produced by the triple gene vector pLIL-2TKSN compared with the titer produced by pLIL-2TKSN or pLXSN. This result suggests that the increase in size and complexity of a retroviral vector could adversely affect viral titer. In order to obtain an improved titer with pLIL-2TKSN, 10 single cell clones, isolated by limiting dilution from the bulk of G418-resistant population, were expanded and further characterized. Viral titers ranged from Ͻ10 2 c.f.u./ml to 1 × 10 5 c.f.u./ml (data not shown). The highest viral titer was produced by clone 3 (pLIL-2TKSN-3) which was used for all our following experiments. NIH 3T3 cells transduced by recombinant virus coming from this clone exhibited resistance to both G418 and HAT medium (data not shown), confirming coherent expression of neo and tk. With the aim of using this retroviral vector for gene therapy of brain tumors, we carried out a series of in vitro experiments using two different glioma cell lines, the AoU373 astrocytoma and the A172 glioblastoma. The efficiency of transduction of pLIL-2TKSN-3 in glioma and NIH 3T3 cells was compared by determining viral titers in each cell line (Table 1) . Titers in AoU373 cells (3 × 10 4 c.f.u./ml) and in A172 cells (2 × 10 3 c.f.u./ml) were one and two logs lower than titer in NIH 3T3 cells (1 × 10 5 c.f.u./ml). These data suggest that the efficacy of treatment using amphotropic retroviral vectors may vary among different gliomas. Polybrene is usually added to the viral supernatants to increase the efficiency of in vitro transduction with retroviral vectors. In contrast, for in vivo applications, polybrene addition to suspensions of retroviral vectors is not foreseen. Therefore, to mimic more closely a real clinical condition, we investigated the effect of lack of polybrene on the efficiency of glioma cell transduction. We found that polybrene has a small effect on viral titers measured in AoU373 and A173 cell lines. Conversely, titer in NIH 3T3 cells was decreased by 25% when polybrene was not added to the viral inoculum (data not shown). An important prerequisite for the use of retroviruses in gene therapy is the complete absence of replication-competent viruses (RCV) in the packaging cell medium. Therefore, we tested the supernatant produced by the packaging cells for the possible presence of RCV that may have been generated through recombination events between the helper genome in PA317 and vectors pLXSN, pLIL-2SN and LIL-2TKSN. A provirus mobilization assay was used to detect any possible helper functions secreted by the packaging cells and transferred to the target cells as described by Cosset et al. 2 No mobilisation was detected using supernatants produced by PA317 cells.
Packaging cells producing the pLIL-2TKSN bicistronic vector were able to secrete variable amounts of biologically active IL-2 as evaluated by the CTLL proliferation assay. This activity was also present in transduced glioma cells. Both A172 and AoU373 cell lines secreted IL-2 (600 or 1000 IU/ml in confluent culture supernatants, respectively), while no IL-2 activity was detected in mock-transduced cells (Figure 2) .
In order to test the functional activity of HSVtk expressed by LIL-2TKSN, we performed in vitro cell killing experiments on transduced human glioma cells. AoU373 and A172 cells were transduced with LIL-2TKSN/3 and selected in the presence of G418. Transduced-resistant bulk cell populations were then plated in the presence of a range of GCV concentrations. In order to estimate the drug dose that inhibited cell growth by 50% (IC 50 ) we used the MTT assay and the trypan blue exclusion method. The two cell lines became sensitive to GCV after virus transduction. An IC 50 of 1 m was found with both methods, a 1000 times lower value than the IC 50 found for parental uninfected cells. Results of the MTT test are shown in Figure 3 . Similar results were obtained with transduced murine NIH 3T3 cells (not shown). Such a sensitivity to GCV exhibited by transduced cells demonstrates the correct functional activity of HSVtk in the triple gene vector pLIL-2TKSN.
In summary, we report the production and characterization of a bicistronic, triple gene retroviral vector (pLIL-2TKSN) aimed at providing a new tool for gene therapy of cancer. Bicistronic vectors designed thus far, generally contain the IRES sequence between a 5′ therapeutic cistron and a 3′ cistron for positive selection. 3, 4 This would ensure that the therapeutic gene is co-selected with the antibiotic resistant gene. In our triple gene vector design, expression of the two therapeutic genes should theoretically be favored over that of the neo gene. The latter gene, in fact, is likely to be transcriptionally disadvantaged for its position within the vector framework and for a negative interference between the SV40 heterologous promoter and the upstream LTR promoter. Notwithstanding, we reasoned that reduced efficiency of the neo gene expression would have been counterbalanced by the selection procedure operating in vitro. One point to be noted is that the structural complexity of the vector Table 1 Transduction efficiency and PA317 (ATCC CRL-9078) amphotropic packaging cells were maintained at 37°C, 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) heat inactivated fetal calf serum, penicillin (100 U/ml) and streptomycin (100 mg/ml). PA317 cells were transfected with pLXSN, pLIL-2SN and pLIL-2TKSN using a calcium phosphate reagent (Boehringer Mannheim) following conditions suggested by the manufacturer. Forty-eight hours after transfection, cells were passaged into growth medium containing 800 g/ml G418 (GIBCO Life Technologies, Grand Island, NY, USA). Following 2-3 weeks selection, G418-resistant populations were obtained. Single cell-derived clones were isolated from the G418-resistant pLIL-2TKSN-transfected PA317 cell population by seeding cells at limiting dilution in 96-well plates in the presence of 800 g/ml G418. Clones were expanded, partially used for further characterization and partially frozen. Infections of NIH 3T3 cells, A172 cells and AoU373 cells for the determination of viral titer, for helper virus detection or other characterization were performed as follows. PA317 producer cells were grown at 37°C in growth medium until confluence was reached. The cells were then incubated at 32°C for 48 h and the growth medium replaced with fresh medium. After 24 h, the virus containing supernatant was harvested, filtered through a 0.45 m pore filter to remove cells and debris and used for infection. Target cells were seeded at 6 × 10 5 cells per well in a 10-cm diameter Petri dish. After overnight incubation, undiluted or serially diluted viral supernatant was plated in the presence or absence of 8 g/ml polybrene (Sigma, St Louis, MO, USA) for 4 h at 37°C after which the viral solution was removed and fresh medium replaced. For virus titer determination or production of stable transfectants, 800 g/ml G418 or an appropriate dilution of HAT medium supplement (Sigma, St Louis, MO, USA) were added to the culture medium to select resistant cells after a 48 h incubation. Virus titer was obtained by counting the number of colonies of resistant cells by methylene blue staining. ND, not done. (4.9 kb) probably affects viral titers. However, a clone could be selected that produced a relatively high number of transducing units (Table 1) and was particularly effective in expressing the therapeutic genes. The construct presented here allows for the combination of the two most promising strategies of gene therapy for cancer, ie tumor suicide and tumor rejection since expression of the therapeutic genes directs enzyme prodrug activation and cytokine production, respectively. The therapeutic genes are expressed by one of the safest viral vectors, ie the Moloney murine leukemia vector, an ideal means for targeting dividing tumor cells in post-mitotic tissues accessible to direct inoculation. Selective integration of the vector only in chromosomes of replicating cells would in fact lead to almost exclusive expression of the transgenes by rapidly growing neoplastic cells and, hopefully, to their selective elimination. Several potential mechanisms of cytokine and suicide gene cooperative antitumor effects can be envisaged. Previous studies indicated that induction of tumor cell cytotoxicity by HSVtk gene transfer and ganciclovir may induce an antitumor immune response in murine syngeneic tumor models. [5] [6] [7] Thus, the use of a bicistronic vector allowing the simultaneous expression of IL-2 and HSVtk may potentiate the induction of an immune response. IL-2 may act in a first phase as an attractant for T cells, which have been shown to migrate in response to IL-2, and may then boost the response of specific CTLs recognizing tumor-associated antigens presented by HLA class-I molecules. In addition, previous studies in nude mice showed that IL-2-engineered human cancer cells are able to induce activation on nonspecific effector cells, leading to tumor rejection and local bystander effects. 8, 9 Neutrophils and activated macrophages, possibily recruited by IL-2 or by other secondary cytokines, predominated in tumor inflammatory infiltrates during the rejection phase. Since macrophages are precursors of dendritic cells, their recruitment by IL-2/HSVtk-transduced cells may be relevant to allow tumor antigen presentation to T helper cells after ganciclovir-triggered tumor cell death. All these phenomena would contribute to the so-called immunity associated with tumor debulking. 10 Another implication of cytokine-driven response is that of favoring increase of the tumor extracellular fluid that would allow better penetration of GCV, notably a hydrophilic molecule. 11 This, in turn, should potentiate prodrug activation by tumor cells, apoptotic cell death and bystander effect through diffusion of toxin metabolites, both gap junction and apoptotic vesicles. [12] [13] [14] [15] This feature may be particularly relevant for tumors of the central nervous system, glioblastoma in particular, which contain a cell fraction in an active state of proliferation, limited amount of tumor extracellular fluid and compact tumor masses. In vitro data presented here produce evidence that glioma cells can be effectively transduced by our vector with high expression of IL-2 (up to 1000 U/ml fluid supernatant), notwithstanding the endogenous production of TGF-␤ by these cells. Reduction of transducing titers by one order of magnitude or more can be explained by down-regulation of the amphotropic receptor in brain tumor cells and/or by low efficiency of the LTR promoter in undifferentiated embryonic-type tumor cells. Both effects may affect the total number of neoresistant colonies. All of these considerations would point to an improvement of pLIL-2TKSN transduction efficiency. This could be achieved by pseudotyping the vector with a heterologous envelope, by using different packaging cell lines and by substituting the endogenous promoter. Combination of a dual strategy that entails gene-directed tumor suicide and tumor rejection has only recently been proposed with AAV and AdV vectors. 16, 17 These vectors, however, seem quite unsuitable for targeting brain tumors owing to the fact that they can effectively transduce resting cells at variance with type C retroviral vectors. We believe the present vector would serve as a useful tool to address this new therapeutic approach.
